Literature DB >> 15047659

Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia.

Youlian Liao1, Soonho Kwon, Sara Shaughnessy, Penny Wallace, Amy Hutto, Alicia J Jenkins, Richard L Klein, W Timothy Garvey.   

Abstract

OBJECTIVE: The goal of this study was to evaluate the efficacy of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) in identifying insulin resistance. RESEARCH DESIGN AND METHODS: This study included 74 nondiabetic Caucasians who were evaluated for insulin resistance and risk factors associated with the metabolic syndrome. Glucose disposal rate (GDR) was measured by hyperinsulinemic-euglycemic clamp and was used to quantify insulin resistance. Sensitivity and specificity of ATP III criteria in detecting insulin resistance were calculated for various cutoffs of GDR.
RESULTS: Insulin resistance was associated with increased waist circumference, fasting glucose, blood pressure, triglycerides, and decreased levels of HDL cholesterol. Only 12.2% of study subjects met ATP III criteria for metabolic syndrome, and ATP III criteria exhibited low sensitivity for detecting insulin resistance. Although high in specificities (>90%), the sensitivities of ATP III criteria ranged only between 20 and 50% when insulin resistance was defined as various GDR cutoff values below 10 to 12 mg.kg(-1).min(-1). The larger number of subjects who were insulin resistant but did not meet ATP III criteria were found to have an adverse cardiovascular disease risk profile, including higher BMI, waist circumference, fasting glucose, triglycerides, and an unfavorable lipoprotein subclass profile determined by nuclear magnetic resonance compared with insulin-sensitive individuals (i.e., increased large VLDL, increased small LDL, and decreased large HDL particle concentrations).
CONCLUSIONS: ATP III criteria have low sensitivity for identifying insulin resistance with dyslipidemia in nondiabetic individuals who are at increased risk for cardiovascular disease and diabetes. More sensitive criteria should be developed for clinical assessment of metabolic and cardiovascular disease risk relevant to the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047659     DOI: 10.2337/diacare.27.4.978

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  45 in total

1.  Insulin resistance is not necessarily an essential element of metabolic syndrome.

Authors:  Rudruidee Karnchanasorn; Horng-Yi Ou; Lee-Ming Chuang; Ken C Chiu
Journal:  Endocrine       Date:  2012-05-29       Impact factor: 3.633

Review 2.  Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training.

Authors:  Christian K Roberts; Andrea L Hevener; R James Barnard
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

3.  Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertension.

Authors:  Egidio Imbalzano; Marco Vatrano; Sebastiano Quartuccio; Rossella Di Stefano; Caterina Oriana Aragona; Federica Mamone; Angela D'Ascola; Michele Scuruchi; Francesca Felice; Giovanni Trapani; Angela Alibrandi; Vincenzo Antonio Ciconte; Roberto Ceravolo; Antonino Saitta; Giuseppe Mandraffino
Journal:  Mol Cell Biochem       Date:  2017-02-11       Impact factor: 3.396

4.  The genetic architecture of lipoprotein subclasses in Gullah-speaking African American families enriched for type 2 diabetes: the Sea Islands Genetic African American Registry (Project SuGAR).

Authors:  Jasmin Divers; Michèle M Sale; Lingyi Lu; Wei-Min Chen; Kerry H Lok; Ida J Spruill; Jyotika K Fernandes; Carl D Langefeld; W Timothy Garvey
Journal:  J Lipid Res       Date:  2009-09-25       Impact factor: 5.922

Review 5.  New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach.

Authors:  W Timothy Garvey
Journal:  Endocr Pract       Date:  2013 Sep-Oct       Impact factor: 3.443

6.  Plasma lipid concentrations in nondiabetic African American adults: associations with insulin resistance and the metabolic syndrome.

Authors:  Elizabeth Stein; Harvey Kushner; Samuel Gidding; Bonita Falkner
Journal:  Metabolism       Date:  2007-07       Impact factor: 8.694

Review 7.  The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  R Kahn; J Buse; E Ferrannini; M Stern
Journal:  Diabetologia       Date:  2005-09       Impact factor: 10.122

Review 8.  Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Ruben-Dario Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

9.  Diagnosis of insulin resistance in hypertensive patients by the metabolic syndrome: AHA vs. IDF definitions.

Authors:  C-M Hwu; C A Hsiung; K-D Wu; W-J Lee; K-C Shih; J Grove; Y-D I Chen; B L Rodriguez; J D Curb
Journal:  Int J Clin Pract       Date:  2008-06-28       Impact factor: 2.503

10.  Waist circumference, not the metabolic syndrome, predicts glucose deterioration in type 2 diabetes.

Authors:  Michael J Blaha; Tebeb Gebretsadik; Ayumi Shintani; Tom A Elasy
Journal:  Obesity (Silver Spring)       Date:  2008-04       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.